Once patents expire for biologic medicines, a market opportunity opens up for biosimilars, a cheaper alternative. With more patents due to expire soon, what will the future look like for biologic medicines?
List view / Grid view
Filter the results
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
Marketing authorisation has been granted by the EC for Evenity® (romosozumab) to treat osteoporosis in postmenopausal women.
A US district court has invalidated Amgen's patent claims for antibodies targeting PCSK9.
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
A federal judge in the US has said that the Trump administration cannot require pharmaceutical companies to include drug prices in advertisements as it is beyond their authority.
Biopharma developers and manufacturers need to know their molecules and understand their manufacturing processes better than ever before. In this article, Mike Wilson discusses the benefits of mass analysis in biopharma and the current challenges of adopting new technologies.
Amgen and Astellas Pharma US have agreed to pay a total of $124.75 million to settle allegations that they paid kickbacks to Medicare copays for their own medications.
A study has reported that almost 40 percent of patients with non-surgically treatable tumours were effectively treated using a genetically modified virus...
First proof-of-concept study shows AMG 714 (anti-IL-15 monoclonal antibody) potentially protects celiac patients from inadvertent gluten exposure
The FDA has approved the use of Prolia for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture...
Phase 1 data supports the use of image-guided therapy for difficult to treat cancer...